[Clinical evaluation of estramustine phosphate and vinblastine in patients with hormone-refractory prostate cancer].

Author: AwakuraY, FukuyamaT, FukuzawaS, ItohN, NonomuraM, YamamotoM

Paper Details 
Original Abstract of the Article :
We evaluated the efficacy of the combination of estramustine phosphate and vinblastine in 13 patients with hormone-refractory prostate cancer. Of 12 patients with an elevated prostate specific antigen (PSA) level at the start of treatment, 5 (42%) had a greater than 50% decrease in PSA level. In a p...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/10965448

データ提供:米国国立医学図書館(NLM)

Estramustine Phosphate and Vinblastine: A New Oasis in the Desert of Prostate Cancer?

Prostate cancer, a common and challenging disease, can become hormone-refractory, meaning that it no longer responds to hormone therapy. This research, like a team of desert explorers seeking a new treatment approach, investigates the efficacy of a combination of estramustine phosphate and vinblastine in treating hormone-refractory prostate cancer. The researchers analyzed data from patients with this condition, aiming to assess the effectiveness of this drug combination and identify potential benefits.

Estramustine Phosphate and Vinblastine: A Glimmer of Hope in the Prostate Cancer Desert?

The researchers observed a response to the treatment in some patients, with a decrease in prostate-specific antigen (PSA) levels and regression of lymph node metastases. This suggests that the combination of estramustine phosphate and vinblastine may hold some promise for treating hormone-refractory prostate cancer, but the researchers acknowledge that further studies are needed to confirm its effectiveness and establish its role in the treatment landscape.

Navigating the Prostate Cancer Desert: A Guide for Patients

This study provides valuable insights into potential treatment options for hormone-refractory prostate cancer. While the results are encouraging, it's crucial to remember that this research involved a small number of patients and further studies are needed to establish the efficacy and safety of this drug combination. If you are diagnosed with prostate cancer, consulting with a qualified oncologist is essential for personalized guidance and treatment options.

Dr.Camel's Conclusion

The desert of prostate cancer can be a challenging and uncertain landscape, but this research offers a glimmer of hope for patients seeking effective treatments. While the combination of estramustine phosphate and vinblastine shows promise, it is essential to consult with a qualified oncologist for personalized guidance and evidence-based treatment options. Remember, just as a camel adapts to survive in the harshest of deserts, so too can individuals with prostate cancer find strength and resilience in their journey toward recovery.

Date :
  1. Date Completed 2000-10-26
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

10965448

DOI: Digital Object Identifier

10965448

Related Literature

SNS
PICO Info
in preparation
Languages

Japanese

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.